Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysisShigeo Shimose, Takuji Torimura, Hiroyuki Suzuki et al.|Oncology Letters|2020Cited by 64
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinomaShigeo Shimose, Takumi Kawaguchi, Atsushi Hiraoka et al.|Hepatology Research|2022Cited by 31
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinomaShigeo Shimose, Takuji Torimura, Atsushi Hiraoka et al.|Scientific Reports|2022Cited by 15